Oral Hedgehog-Pathway Inhibitors for Basal-Cell Carcinoma
Author:
- 7 June 2012
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 366 (23) , 2225-2226
Abstract
Basal-cell carcinoma of the skin is the most common cancer worldwide, and its prevalence is increasing, accounting for 80% of nonmelanoma skin cancers.1 In 2006, more than 2.1 million new cases of nonmelanoma skin cancer were treated in the United States.2 Basal-cell carcinoma has many clinical subtypes and can progress to an advanced state in which surgery or radiation therapy is not considered to be helpful (locally advanced basal-cell carcinoma). Such lesions arise either from earlier lesions that have not been treated or from a recurrence of aggressive basal-cell carcinoma. Metastatic basal-cell carcinoma is rare.1 Exposure to ultraviolet light is . . .Keywords
This publication has 7 references indexed in Scilit:
- Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus SyndromeNew England Journal of Medicine, 2012
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006Archives of Dermatology, 2010
- Non-melanoma skin cancerThe Lancet, 2010
- Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in MedulloblastomaScience, 2009
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2009
- Identification of Mutations in the Human PATCHED Gene in Sporadic Basal Cell Carcinomas and in Patients with the Basal Cell Nevus SyndromeJournal of Investigative Dermatology, 1998